Public Health
O'shea, S. H., Schwarz, J., Kosyk, O., Ross, P.K., Ha, M. J., Wright, F. A., & Rusyn, I. In vitro screening for population variability in chemical toxicity. (2010) Toxicological Sciences 119(2), 398-407.
PAPER
Wright FW, Sullivan P, Brooks A, Zou F, Sun W, Xia K, Madar V, Abdellaoui A, Batista S, Butler C, Chen G, Chen T, Chung W, D’Ambrosio D, de Geus E, Gallins P, Ha MJ, Hottenga J, Huang S, Jansen R, Kattenberg M, Kochar J, Middeldorp C, Qu A, Shabalin A, Smit J, Tischfield J, Tzeng J, van Grootheest G, Vink J, Wang Q, Wang W, Wang W, Willemsen G, Yin Z, Zhou Y, Penninx B & Boomsma D. Heritability and genomics of gene expression in peripheral blood. (2014) Nature Genetics 46(5), 430-437.
Yang, Q., Chen, L. S., Ha, M. J., Do, K. A., Neelapu, S. S., & Gandhi, V. Idelalisib impacts cell growth through inhibiting translation-regulatory mechanisms in mantle cell lymphoma. (2017) Clinical Cancer Research, 23(1), 181-192.
Jones, R.J., Singh, R.K., Shirazi, F., Wan, J., Wang, H., Wang, X., Ha, M.J., Baljevic, M., Kuiatse, I., Davis, R.E. and Orlowski, R.Z.
Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.
Frontiers in immunology 11, 1816. (2020)
Ha, M.J.*, Kim, J., Galloway-Pena, J., Do, K.A. and Peterson, C.B.
Compositional zero-inflated network estimation for microbiome data.
BMC bioinformatics 21(21), 1-20. (2020)
Burke, S., Mork, M., Qualmann, K., Woodson, A., Ha, M.J., M., Arun, B. and Kaulfus, M.
Genetic counselor approaches to BRCA1/2 direct-to-consumer genetic testing results.
Journal of Genetic Counseling 30(3), 803-812.(2021)
Lee, S. H., Yim, S. Y., Jeong, Y. S., Li, Q.-X., Kang, S.-H., Sohn, B. H., Kumar, S. V., Shin, J.-H., Choi, Y. R., Shim, J.-J., Kim, H., Kim, J., Kim, S., Guo, S., Johnson, R. L., Kaseb, A., Kang, K. J., Chun, Y. S., Jang, H. J., Ha, M. J., Akbani, R., Roberts, L. R., Wheeler, D. A., & Lee, J.-S.
Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes, response to therapies, and multiple biomarkers.
Hepatology. 76(6), 1634-1648. (2022)
Jang, Y. S., Yoon, N.-Y., Hurh, K., Park, E.-C., & Ha, M. J. *
Association between changes in having of cancer patients in the family and depression: A longitudinal panel study
Journal of Affective Disorders, 333, 482-488. (2023)
Kim, J., Hurh, K., Kim, H., Park, E.-C., & Ha, M. J. *
Effect of the peripartum depressive symptoms on the Internet use disorder of their offspring in late childhood: retrospective longitudinal study
Scientific Reports, 14(1), p.417. (2024)
Thongon, N., Ma, F., Baran, N., Lockyer, P., Liu, J., Jackson, C., Rose, A., Furudate, K., Wildeman, B., Marchesini, M., Marchica, V., Storti, P., Todaro, M., Ganan-Gomez, I., Adema, V., Rodriguez-Sevilla, J. J., Qing, Y., Ha, M. J., Fonseca, R., et al.
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma.
Nature Communications. 15(1), 1203. (2024).
Ko, A. J., Kim, J., Park, E.-C., & Ha, M. J. *
Association between the utilization of senior centers and participation in health check-ups.
Sci Rep 14, 11518 (2024).
Kim, C. R., Kim, S. Y., Kim, J., Park, E.-C., & Ha, M. J. *
Association between sleep patterns and alcohol use disorders in workers.
PLOS ONE. 19(8): e0308418. (2024).
Le, H. T., Do, T. H., Dao, T. A., Hoang, T. T., Nguyen, B. T., Le, T. L., Nguyen, D. L., Yoshida, L. M., Le, X. H., Le, H. Q., Ton, T. T., & Ha, M. J. *
Seroprevalence of anti-diphtheria toxoid antibody and implications for vaccination policy in Vietnam’s South-central coast: a cross-sectional study.
BMC Infectious Diseases 24, 813(2024).
Ko, A. J., Kim, J., Park, E.-C., & Ha, M. J.
Is engagement in social activities with peers within senior centers associated with participation in health check-ups?
Research Square. (2024).
Kim, J., Yun, I., Park, E.-C., & Ha, M. J.
Effectiveness of primary care-based chronic disease management program on glycated hemoglobin levels.
Research Square. (2024).
Kim, J., Kim, H., Park, E.-C., & Ha, M. J.
Association of physical activity with risk of dementia in geriatric depression patients.
Research Square. (2024).
Osei, K. M., Awog-badek, A. A., Prasiska, D. I., Chapagain, D. D., & Ha, M. J.
Impact of Ghana’s fee exemption policy on maternal health service utilisation: An inverse probability of treatment weighting analysis of pooled national data.
Journal of Global Health, 15, 04058. (2025).
Park, S. M., Joo, M. J., Lim, J. H., Jang, S.-Y., Park, E.-C., & Ha, M. J.
Association between hikikomori (social withdrawal) and depression in Korean young adults.
Journal of Affective Disorders, 380, 647–654. (2025).
Lim, J. H., Joo, M. J., Ko, J., Kim, D. B., Park, E.-C., & Ha, M. J.
Impact of fear of falling on social engagement among older adults: A nationwide longitudinal panel study.
The Journal of Nutrition, Health and Aging, 29, 100589. (2025).
CANCER
Hunt, K. K., Karakas, C., Ha, M. J., Biernacka, A., Yi, M., Sahin, A., ... & Cheung, K. L.
Cytoplasmic cyclin E predicts recurrence in patients with breast cancer.
Clinical Cancer Research 23(12), 2991-3002. (2016)
Kettner, N. M., Vijayaraghavan, S., Durak, M. G., Bui, T., Kohansal, M., Ha, M. J., Liu, B., Rao, X., Wang, J., Yi, M., & Carey, J. P.
Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer.
Clinical Cancer Research 25(13), 3996-4013 (2019)
Meraz, I., Majidi, M., Meng, F., Shao, R., Ha, M. J., Neri, S., Fang, B., Lin, S., Tinkey, P., Shpall, E., Morris, J., & Roth, J.
Development of an improved humanized patient-derived xenograft mouse model for evaluation of antitumor immune response in lung cancer.
Cancer Immunology Research 79(13) (2019)
Meraz, I. M., Majidi, M., Meng, F., Shao, R., Ha, M. J., Neri, S., Fang, B., Lin, S. H., Tinkey, P. T., Shpall, E. J., Morris, J., & Roth, J. A.
An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses.
Cancer Immunology Research7(8):1267-1279. (2019)
Jones, R. J., Singh, R. K., Shirazi, F., Wan, J., Wang, H., Wang, X., Ha, M. J., Baljevic, M., Kuiatse, I., Davis, R. E., & Orlowski, R. Z.
Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.
Front Immunol. 11:1816. (2020)
Karakas, C., Francis, A., Ha, M. J.*, Wingate, H., Meena, R., Yi, M., Rasaputra, K., Gutierrez-Barrera, A., Arun, B., Do, K. A., Sahin, A., Keyomarsi, K., & Hunt, K.
Cytoplasmic cyclin E expression predicts for response to neoadjuvant chemotherapy in breast cancer.
Annals of Surgery 274(2), e150. (2020)
Chun, Y. S., Mizuno, T., Cloyd, J. M., Ha, M. J., Omichi, K., Tzeng, C. W. D., Aloia, T. A., Ueno, N. T., Kuerer, H. M., Barcenas, C. H., & Vauthey, J. N.
Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes.
European Journal of Surgical Oncology 46(9), 1588-1595. (2020)
Long, J. P., Irajizad, E., Doecke, J. D., Do, K.-A., & Ha, M. J.
A framework for mediation analysis with multiple exposures, multivariate mediators, and non-linear response models
arXiv, 2011.00601 (2020).
Zhang, X., Zhang, R., Chen, H., Wang, L., Ren, C., Pataer, A., Wu, S., Meng, Q. H., Ha, M. J., Morris, J., & Xi, Y.
KRT-232 and navitoclax enhance trametinib’s anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations.
American journal of cancer research 10(12), 4464.(2020)
Chen, X., Yang, D., Carey, J., Karakas, C., Albarracin, C., Sahin, A., Arun, B., Durak, M. G., Li, M., Kohansal, M., Bui, T., Ha, M. J., Hunt, K., & Keyomarsi, K.
Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration.
Cancers 13(7) (2021)
Lulla, A. R., Akli, S., Karakas, C., Ha, M. J.*, Fowlkes, N. W., Mitani, Y., Bui, T., Wang, J., Rao, X., Hunt, K. K., Meijer, L., El-Naggar, A. K., & Keyomarsi, K.
LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers.
Oncogenesis 10(5), 40. (2021)
Robichaux, J. P., Le, X., Vijayan, R. S. K., Hicks, J. K., Heeke, S., Elamin, Y. Y., Lin, H. Y., Udagawa, H., Skoulidis, F., Tran, H., Varghese, S., He, J., Zhang, F., Nilsson, M. B., Hu, L., Poteete, A., Rinsurongkawong, W., Zhang, X., Ren, C., Liu, X., Hong, L., Zhang, J., Diao, L., Madison, R., Schrock, A. B., Saam, J., Raymond, V., Fang, B., Wang, J., Ha, M. J., Cross, J. B., Gray, J. E., & Heymach, J. V.
Structure-based classification predicts drug response in EGFR mutant NSCLC.
Nature 597(7878), 732-737. (2021)
Chakraborty, M., Baladandayuthapani, V., Bhadra, A., & Ha, M. J.
Bayesian Robust Learning in Chain Graph Models for Integrative Pharmacogenomics.
arXiv preprint arXiv:2111.11529. (2021)
Long, J. P., Zhu, H., Do, K.-A., & Ha, M. J.
The Generalized Causal Dantzig: A unified Approach to Instruments and Environments
arXiv, arXiv:2207.14753. (2022)
Majidi, M., Shao, R., Meng, F., Ha, M. J., Shpall, E., Roth, J., & Meraz, I.
TUSC2 immunogene therapy synergizes with chemoimmunotherapy through central and effector memory T cell upregulation to eradicate Kras/LKB1(STK11) mutant non-small cell lung cancer (NSCLC).
Communications Biology 5 (1), 1-13. (2022)
Ha, M. J., Raghavendra, A. S., Kettner, N. M., Hunt, K. K., Shen, Y., Tripathy, D., & Keyomarsi, K.
Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients as compared to endocrine therapy alone-A real world study.
International Journal of Cancer 150(12), 2025-2037. (2022)
Pairawan, S., Akcakanat, A., Kopetz, S., Tapia, C., Zheng, X., Rizvi, Y., Holla, V., Wang, J., Ha, M. J., Evans, K., Busaidy, N., Fang, B., Roth, J., Dumbrava, E. I., & Meric-Bernstam, F.
Combined MEK/MDM2 Inhibitors Demonstrates Antitumor Efficacy in TP53 Wild-Type Thyroid and Colorectal Cancers with MAPK Alterations.
Scientific Reports 12 (1), 1-15. (2022+)
Meraz, I. M., Majidi, M., Fang, B., Meng, F., Gao, L., Shao, R., Song, R., Li, F., Lissanu, Y., Chen, H., Ha, M. J., Wang, Q., Wang, J., Shpall, E., Jung, S. Y., Haderk, F., Gui, P., Riess, J. W., Olivas, V., Bivona, T. G., & Roth, J. A.
3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib .
Communications Biology 6 (1), 509. (2023)
Saridogan, T., Akcakanat, A., Zhao, M., Evans, K. W., Yuca, E., Scott, S., Kirby, B. P., Zheng, X., Ha, M. J., Chen, H., Ng, P. K. S., DiPeri, T. P., Mills, G. B., Rodon Ahnert, J., Damodaran, S., & Meric-Bernstam, F.
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer.
Scientific reports 13, no. 1. (2023)
Meric-Bernstam, F., Lloyd, M. W., Koc, S., Evrard, Y. A., McShane, L. M., Lewis, M. T., Evans, K. W., Rubinstein, L., Welm, A., Dean, D. A., Srivastava, A., Grover, J. W., Ha, M. J., Chen, H., Huang, X., Varadarajan, K., Wang, J., Roth, J. A., Welm, B. E., Govindan, R., Ding, L., Kaochar, S., Mitsiades, N., Carvajal-Carmona, L., Herlyn, M., Davies, M. A., Shapiro, G. I., Fields, R., Trevino, J. G., Harrell, J. C., Doroshow, J. H., Chuang, J. H., & Moscow, J. A.
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations
Molecular Cancer Therapeutics 23(7), 924-938. (2024).